MPLT
NASDAQMapLight Therapeutics Inc.
News25/Ratings7
News · 26 weeks59+150%
2025-10-262026-04-19
Mix4290d
- Insider29(69%)
- SEC Filings8(19%)
- Analyst3(7%)
- Other2(5%)
Latest news
25 items- INSIDERSEC Form 4 filed by Foff Erin Pennock4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERSEC Form 4 filed by Lillie James Woodruff4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERSEC Form 4 filed by Hanson Kristopher4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERSEC Form 4 filed by Gillis Jonathan4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERSEC Form 4 filed by Kreitzer Anatol4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERSEC Form 4 filed by Setia Vishwas4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERSEC Form 4 filed by Kroeger Christopher A.4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERSEC Form 4 filed by Malenka Robert C.4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- SECSEC Form 144 filed by MapLight Therapeutics Inc.144 - MapLight Therapeutics, Inc. (0001770069) (Subject)
- SECAmendment: SEC Form 144/A filed by MapLight Therapeutics Inc.144/A - MapLight Therapeutics, Inc. (0001770069) (Subject)
- SECAmendment: SEC Form 144/A filed by MapLight Therapeutics Inc.144/A - MapLight Therapeutics, Inc. (0001770069) (Subject)
- SECSEC Form 144 filed by MapLight Therapeutics Inc.144 - MapLight Therapeutics, Inc. (0001770069) (Subject)
- SECSEC Form 144 filed by MapLight Therapeutics Inc.144 - MapLight Therapeutics, Inc. (0001770069) (Subject)
- ANALYSTNeedham initiated coverage on MapLight Therapeutics with a new price targetNeedham initiated coverage of MapLight Therapeutics with a rating of Buy and set a new price target of $37.00
- ANALYSTTD Cowen initiated coverage on MapLight TherapeuticsTD Cowen initiated coverage of MapLight Therapeutics with a rating of Buy
- SECSEC Form S-8 filed by MapLight Therapeutics Inc.S-8 - MapLight Therapeutics, Inc. (0001770069) (Filer)
- SECSEC Form 10-K filed by MapLight Therapeutics Inc.10-K - MapLight Therapeutics, Inc. (0001770069) (Filer)
- SECMapLight Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - MapLight Therapeutics, Inc. (0001770069) (Filer)
- PRMapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatePhase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected to reach target enrollment (n=300) in April 2026, with topline results expected in the third quarter of 2026Phase 2 IRIS trial for ML-004 for autism spectrum disorder has completed enrollment, with topline results expected in the third quarter of 2026Received FDA Fast Track designation for ML-007C-MA for Alzheimer's disease psychosis; topline results from Phase 2 VISTA trial expected in the second half of 2027Expanded pipeline with a next-generation M1/M4 muscarinic agonist program, ML-055, with candidate nomination expected in 2026Ended the year with $453.1 million in cash, cash equivalents and investments, which is expected to f
- ANALYSTCanaccord Genuity initiated coverage on MapLight Therapeutics with a new price targetCanaccord Genuity initiated coverage of MapLight Therapeutics with a rating of Buy and set a new price target of $35.00
- PRMapLight Therapeutics to Participate in Upcoming Investor ConferencesSAN FRANCISCO and BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (NASDAQ:MPLT) today announced that members of its management team will participate in the following investor conferences: Event: Jefferies 2026 Biotech on the Beach Summit (Miami, FL)Date: Tuesday, March 10thFormat: Hosting 1x1 meetings Event: Leerink 2026 Global Healthcare Conference (Miami, FL)Date: Wednesday, March 11thFormat: Presenting and hosting 1x1 meetings Event: Stifel 2026 Virtual CNS ForumDate: Wednesday, March 18thFormat: Presenting and hosting 1x1 meetings Where available, access to the live webcasts of these events, as well as archived recordings, will be posted under the "Events & P
- INSIDERDirector Malenka Robert C. sold $260,398 worth of Voting Common Stock (14,195 units at $18.34), decreasing direct ownership by 4% to 325,059 units (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERDirector Pavlov George bought $441,168 worth of Voting Common Stock (25,000 units at $17.65) (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERDirector Malenka Robert C. sold $220,632 worth of Voting Common Stock (12,116 units at $18.21), decreasing direct ownership by 3% to 339,254 units (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERDirector Malenka Robert C. sold $124,329 worth of Voting Common Stock (6,863 units at $18.12), decreasing direct ownership by 2% to 351,370 units (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)